1. Home
  2. FHTX vs NBP Comparison

FHTX vs NBP Comparison

Compare FHTX & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

SELL

Current Price

$1.77

Market Cap

111.1M

Sector

Health Care

ML Signal

SELL

NBP

NovaBridge Biosciences American Depositary Shares

HOLD

Current Price

$0.83

Market Cap

96.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FHTX
NBP
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
111.1M
96.0M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
FHTX
NBP
Price
$1.77
$0.83
Analyst Decision
Buy
Strong Buy
Analyst Count
10
3
Target Price
$4.17
★ $8.67
AVG Volume (30 Days)
★ 647.0K
528.9K
Earning Date
11-09-2026
08-20-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 25.32
N/A
EPS
★ 0.43
N/A
Revenue
★ $30,909,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.17
★ N/A
Revenue Growth
★ 36.75
N/A
52 Week Low
$1.77
$0.77
52 Week High
$7.61
$5.19

Technical Indicators

Market Signals
Indicator
FHTX
NBP
Relative Strength Index (RSI) 33.34 20.60
Support Level N/A N/A
Resistance Level $2.28 $1.45
Average True Range (ATR) 0.18 0.07
MACD 0.05 -0.01
Stochastic Oscillator 8.18 9.25

Price Performance

Historical Comparison
FHTX
NBP

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

About NBP NovaBridge Biosciences American Depositary Shares

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

Share on Social Networks: